JOSEPH LAU: Open Payments
NPI 1619438389 · HENDERSON, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,728 in 43 payments from 22 companies in 2025. Trend: 2023 $3,744 · 2024 $3,559 · 2025 $3,728
Food & beverage: $3,728
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 6 | $716 |
| Novo Nordisk Inc | 11 | $573 |
| Abbott Laboratories | 3 | $390 |
| Dexcom, Inc. | 2 | $163 |
| Daiichi Sankyo Inc. | 2 | $156 |
| BeOne Medicines USA, Inc. | 1 | $149 |
| Genmab U.S., Inc. | 1 | $125 |
| Vifor Pharma, Inc. | 1 | $125 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $124 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $122 |
Products named: QULIPTA, Wegovy, FREESTYLE LIBRE 3, VRAYLAR, Dexcom G6 Transmitter, INJECTAFER, TEVIMBRA, Ozempic.
Industry payments across NV — which companies pay providers there.
